SPAGO NANOMEDICAL AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.314 SEK | -1.88% |
|
+3.97% | -3.98% |
| 05-20 | Spago Nanomedical Provides an Update on Tumorad-01, Trial Proceeds as Planned | CI |
| 05-02 | Spago Nanomedical AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 315.4 | 270 | 197.7 | 57.29 | 71.37 | 109.3 | - | - |
| Enterprise Value (EV) 1 | 303.3 | 270 | 197.7 | -4.806 | 26.16 | 73.53 | 73.33 | 10.33 |
| P/E ratio | -14.9 x | -12.2 x | -4.85 x | - | -0.76 x | -4.49 x | -2.17 x | 6.28 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 10,515 x | 790 x | 300 x | 54.4 x | 59.3 x | 3.82 x | 7.65 x | 0.59 x |
| EV / Revenue | 10,110 x | 790 x | 300 x | -4.56 x | 21.7 x | 2.57 x | 5.13 x | 0.06 x |
| EV / EBITDA | -15.3 x | -14.5 x | -5.09 x | 0.12 x | -0.61 x | -2.33 x | -1.45 x | 0.27 x |
| EV / FCF | -14.2 x | -13.9 x | -5.5 x | 0.13 x | -0.58 x | -2.58 x | -1.48 x | 0.34 x |
| FCF Yield | -7.03% | -7.18% | -18.2% | 794% | -172% | -38.8% | -67.5% | 290% |
| Price to Book | 2.29 x | 1.69 x | 1.07 x | - | 1.72 x | 7.85 x | 10.5 x | 15.7 x |
| Nbr of stocks (in thousands) | 21,030 | 31,545 | 41,182 | 90,944 | 218,265 | 348,196 | - | - |
| Reference price 2 | 15.00 | 8.560 | 4.800 | 0.6300 | 0.3270 | 0.3140 | 0.3140 | 0.3140 |
| Announcement Date | 30/01/20 | 02/02/21 | 02/02/22 | 02/02/23 | 07/02/24 | - | - | - |
1SEK in Million2SEK
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.03 | 0.342 | 0.66 | 1.054 | 1.203 | 28.6 | 14.3 | 185.1 |
| EBITDA 1 | -19.85 | -18.6 | -38.82 | -39.11 | -42.79 | -31.55 | -50.6 | 37.85 |
| EBIT 1 | -20.21 | -18.96 | -39.19 | -39.46 | -43.07 | -31.7 | -50.75 | 37.75 |
| Operating Margin | -67,370% | -5,544.44% | -5,938.18% | -3,744.31% | -3,580.47% | -110.84% | -354.9% | 20.39% |
| Earnings before Tax (EBT) 1 | -20.21 | -18.93 | -39.07 | - | -42.22 | -31.25 | -50.75 | 37.75 |
| Net income 1 | -20.21 | -18.93 | -39.07 | - | -42.22 | -31.25 | -50.75 | 32.35 |
| Net margin | -67,370% | -5,534.5% | -5,919.85% | - | -3,509.81% | -109.27% | -354.9% | 17.48% |
| EPS 2 | -1.010 | -0.7000 | -0.9900 | - | -0.4300 | -0.0700 | -0.1450 | 0.0500 |
| Free Cash Flow 1 | -21.34 | -19.38 | -35.94 | -38.19 | -45.06 | -28.5 | -49.5 | 30 |
| FCF margin | -71,116.67% | -5,666.08% | -5,445.76% | -3,623.06% | -3,745.8% | -99.65% | -346.15% | 16.21% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | 79.26% |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | 92.74% |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 30/01/20 | 02/02/21 | 02/02/22 | 02/02/23 | 07/02/24 | - | - | - |
1SEK in Million2SEK
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q2 | 2023 Q3 | 2023 Q4 |
|---|---|---|---|
| Net sales | - | - | - |
| EBITDA | - | - | - |
| EBIT 1 | - | -7.308 | -9.586 |
| Operating Margin | - | - | - |
| Earnings before Tax (EBT) | - | - | - |
| Net income 1 | -7.866 | -7.113 | -9.417 |
| Net margin | - | - | - |
| EPS | -0.0900 | - | - |
| Dividend per Share | - | - | - |
| Announcement Date | 31/07/23 | 03/11/23 | 07/02/24 |
1SEK in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 12.1 | - | - | 62.1 | 45.2 | 35.8 | 36 | 99 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -21.3 | -19.4 | -35.9 | -38.2 | -45.1 | -28.5 | -49.5 | 30 |
| ROE (net income / shareholders' equity) | -15.6% | -12.7% | - | -20.5% | -35.4% | -30% | -75% | 118% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share 2 | 6.540 | 5.060 | 4.490 | - | 0.1900 | 0.0400 | 0.0300 | 0.0200 |
| Cash Flow per Share | -1.060 | - | - | - | - | - | - | - |
| Capex 1 | - | - | - | - | - | 0.5 | 1 | 1 |
| Capex / Sales | - | - | - | - | - | 1.75% | 6.99% | 0.54% |
| Announcement Date | 30/01/20 | 02/02/21 | 02/02/22 | 02/02/23 | 07/02/24 | - | - | - |
1SEK in Million2SEK
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -3.98% | 10.45M | |
| -40.52% | 8.12B | |
| +9.28% | 3.62B | |
| -23.85% | 1.92B | |
| -20.90% | 1.66B | |
| +7.02% | 931M | |
| +16.42% | 729M | |
| -8.73% | 694M | |
| -34.69% | 472M | |
| +1.59% | 295M |
- Stock Market
- Equities
- SPAG Stock
- Financials Spago Nanomedical AB
